From Yahoo Finance: 2025-05-27 10:03:00

Jim Cramer discussed Sarepta Therapeutics Inc. (NASDAQ: SRPT), a biotech firm focusing on RNA therapies for rare neuromuscular diseases like Duchenne muscular dystrophy. Despite initial cautious optimism, the stock dropped 68.98%. Cramer later expressed concern about RNA-based therapeutic companies. SRPT ranks 2nd on his list, but other AI stocks may offer better returns with less risk.



Read more at Yahoo Finance: Was Jim Cramer Right About Sarepta Therapeutics Inc. (SRPT)?